Company profile
Covid-19 Antibody Immunity Test | Attomarker
Providing nationally available Covid-19 Antibody Immunity Test & Profile, allowing you to better understand your immunity and protection.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
RP04SH01 | Transaction MzQ0MTg2NDM4N2FkaXF6a2N4
Published 06 Nov 2024 10:54
SH01 | Transaction MzQzOTMyNTczMmFkaXF6a2N4 | Paper/PDF filed
Published 07 Nov 2024 07:04
Company registered at Companies House
Attomarker has developed antibody screening and blood profiling technology to allow the human body's reaction to inflammation, differential diagnosis and recovery to be observed.
Attomarker is developing the array reader technology for commercialsiation and has currently had to small funding rounds and is seeking a larger funding round, The company is exploring application in the fields of point-of-care testing and providing services for the immunotherapy markets. It has secured seed funding and will close Series A and Series B funding in March 2017. The company will launch product in November 2017 and head to sales in summer of 2018.
The company aims to change public health triage especially with complex infections.
1 Dec 2020 to 30 Nov 2021
This project is focused on the development of two rapid, point-of-care COVID-19/flu tests that can be used to test a person for both coronavirus and flu antigens (showing whether they currently HAVE either of the viruses) and antibodies (showing whether they have previously HAD the viruses). The tests would take 5-7 mins to complete and thus results could...
